ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress
According to U.S. Centers for Disease Control and Prevention, pertussis affects approximately 16 million people each year globally, accounting for nearly 200,000 deaths.
- According to U.S. Centers for Disease Control and Prevention, pertussis affects approximately 16 million people each year globally, accounting for nearly 200,000 deaths.
- Pertussis is highly contagious, and an infected person can transmit B. pertussis to as many as 15 other people.
- ILiAD Biotechnologies is utilizing proprietary B-Tech technology to develop next generation vaccines to prevent infectious diseases and improve lives.
- Its lead candidate, BPZE1, is the most advanced next generation vaccine for immunization against pertussis (whooping cough), a serious disease caused by Bordetella pertussis.